Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,067Revenue $M173Net Margin (%)-880.1Z-Score36.6
Enterprise Value $M1,000EPS $3.3Operating Margin %-1,081.3F-Score5
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-1,080.1Higher ROA y-yY
Price/Book16.910-y EBITDA Growth Rate %0Quick Ratio10.9Cash flow > EarningsY
Price/Sales3285-y EBITDA Growth Rate %0Current Ratio10.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-40.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-48.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M28.0ROI % (ttm)-59.8Gross Margin Increase y-yN

Gurus Latest Trades with NLNK

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NLNKJean-Marie Eveillard 2014-03-31 Add0.02%$21.38 - $50.4
($33.68)
$ 43.0828%Add 28.35%1,161,805
NLNKJean-Marie Eveillard 2013-09-30 Add0.01%$15.78 - $20.08
($17.83)
$ 43.08142%Add 21.32%778,354
NLNKJean-Marie Eveillard 2013-06-30 Add0.02%$11.27 - $22.56
($15.73)
$ 43.08174%Add 95.04%641,554
NLNKJean-Marie Eveillard 2013-03-31 Buy 0.01%$11.4 - $12.7
($12.08)
$ 43.08257%New holding, 328939 sh.328,939
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NLNK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NLNK Jean-Marie Eveillard 2014-12-311,406,3865.030.14+11.83%
NLNK - CALLJean-Marie Eveillard 2014-12-3112,3750.040.03
Premium Most recent portfolio changes are included for Premium Members only!


NLNK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Wiley BrianVP of Business Development 2015-02-17Sell10,000$40.077.51view
Ramsey William J.Quality Assurance Officer 2015-02-17Sell2,500$407.7view
Link Charles J. Jr.Chairman of the Board and CEO 2015-02-05Sell20,000$32.4132.92view
Ramsey William J.Quality Assurance Officer 2015-01-23Sell2,500$407.7view
Link Charles J. Jr.Chairman of the Board and CEO 2015-01-07Sell20,000$37.9913.4view
Wiley BrianVP of Business Development 2015-01-02Sell20,000$40.336.82view
Link Charles J. Jr.Chairman of the Board and CEO 2014-12-04Sell20,000$37.8413.85view
HENNEMAN JOHN B IIIEVP, CFO 2014-11-25Buy5,000$34.3525.41view
Link Charles J. Jr.Chairman of the Board and CEO 2014-11-10Sell20,000$32.9430.78view
LINK GORDON H JRCFO 2014-10-24Sell2,500$40.396.66view

Press Releases about NLNK :

    Quarterly/Annual Reports about NLNK:

    News about NLNK:

    Articles On GuruFocus.com
    NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
    Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 

    More From Other Websites
    Decision on Ebola mass vaccination in August at earliest - WHO Feb 27 2015
    Decision on Ebola mass vaccination in August at earliest - WHO Feb 27 2015
    Decision on widespread Ebola vaccination in August at earliest - WHO Feb 27 2015
    Decision on widespread Ebola vaccination in August at earliest - WHO Feb 27 2015
    NewLink beats 4Q profit forecasts Feb 26 2015
    NewLink beats 4Q profit forecasts Feb 26 2015
    NewLink Genetics Corporation Provides Operational Update and Reports Fourth Quarter and Year End... Feb 26 2015
    NewLink Genetics Corporation Provides Operational Update and Reports Fourth Quarter and Year End... Feb 26 2015
    Medicago wins contract to develop Ebola treatments Feb 24 2015
    Medicago wins contract to develop Ebola treatments Feb 24 2015
    NewLink Genetics Corporation Announces Clinical Development Milestone Achieved With Merck for Ebola... Feb 19 2015
    NEWLINK GENETICS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 19 2015
    NewLink Genetics Corporation Announces Clinical Development Milestone Achieved With Merck for Ebola... Feb 19 2015
    NewLink Genetics to Host Its Fourth Quarter and Year End 2014 Financial Results Conference Call on... Feb 19 2015
    NewLink Genetics to Participate in the SunTrust Robinson Humphrey Orphan Drug Day Feb 17 2015
    NewLink Genetics to Participate in the SunTrust Robinson Humphrey Orphan Drug Day Feb 17 2015
    TrovaGene Partners with Leading Cancer Research Institutes - Analyst Blog Jan 26 2015
    Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst Blog Jan 22 2015
    NewLink Genetics to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 07 2015
    NewLink Genetics to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 07 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK